Chen et al. 2019 first suggested that lysyl oxidase inhibitors prevent the chemoattraction of tumor-associated macrophages (TAMs, pro-tumorigenic) in preclinical models of glioblastoma [191]. Here, LOX is linked to glioblastoma.